AEI This Week
Mar 21, 2020
AEI's weekly digest of top commentary and scholarship on the issues that matter most
 
 
Washington’s response to the virus
 
Photo
Reuters
 
At this stage in the crisis, it seems that many key officials are doing many important things right yet they also have to work around some serious decisional dysfunction at the top, explains Yuval Levin.
 
 
fb.png
twitter.png
email.png
 
 
Send in the Marines? Not to fight coronavirus
 
Photo
Twenty20
 
Kori Schake gives some guidelines of things the president and Defense Department should do — and avoid doing — to ensure that they don’t create dangerous precedents in American civil-military relations.
 
 
fb.png
twitter.png
email.png
 
 
American hospitals can avoid Italy’s fate
 
Photo
Twenty20
 
Scott Gottlieb and Luciana Borio write that Italy and China proved that the only way to save lives is to make sure the medical system can keep pace with the need for critical care.
 
 
fb.png
twitter.png
email.png
 
 
Strong competition among US airlines before COVID-19 pandemic
 
Photo
Reuters
 
Over the past 15 years, airlines have become more apt to compete head-to-head over routes, making air travel more affordable even as the number of airlines has decreased, write Scott Ganz and Burke O'Brien. The data make a compelling case that competition among airlines was stronger than ever before the COVID-19 pandemic.
 
 
fb.png
twitter.png
email.png
 
 
Reforming ‘reform conservatism’?
 
Photo
Twenty20
 
The 2016 election confirmed the reformocon analysis of Republican politics while removing some of the barriers to the pursuit of reform. The question is not whether reform conservatism has a future. It is what shape that future will take, writes Matthew Continetti.
 
 
fb.png
twitter.png
email.png
 
 
 
fb.png
twitter.png
 
 
 
research spotlight
 
 
Advancing treatments to save lives and reduce the risk of COVID-19
 
Photo
Reuters
 
We need to determine which treatments work best to advance safe and effective products to market efficiently and to enable access to promising treatments for patients who might benefit from them now, explain Scott Gottlieb and Mark McClellan.
 
fb.png
twitter.png
email.png